RecruitingPhase 2NCT06812078
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
Studying Idiopathic hypersomnia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Takeda
- Principal Investigator
- Study DirectorTakeda
- Intervention
- TAK-360(drug)
- Enrollment
- 96 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2025 – 2026
Study locations (29)
- Takeda Site 11, Redwood City, California, United States
- Takeda Site 10, Santa Ana, California, United States
- Takeda Site 27, Colorado Springs, Colorado, United States
- Takeda Site 19, Brandon, Florida, United States
- Takeda Site 14, Winter Park, Florida, United States
- Takeda Site 29, St Louis, Missouri, United States
- Takeda Site 16, Denver, North Carolina, United States
- Takeda Site 15, Huntersville, North Carolina, United States
- Takeda Site 12, Cincinnati, Ohio, United States
- Takeda Site 17, Cincinnati, Ohio, United States
- Takeda Site 13, Columbia, South Carolina, United States
- Takeda Site 18, San Antonio, Texas, United States
- Takeda Site 28, Norfolk, Virginia, United States
- Takeda Site 1, Montpellier, Hrault, France
- Takeda Site 3, Nantes, Pays de Loire, France
- +14 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06812078 on ClinicalTrials.govOther trials for Idiopathic hypersomnia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07500090A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)Harmony Biosciences Management, Inc.
- RECRUITINGNCT06732284Study of Sleep Inertia in Major Depressive Disorder by the Psychomotor Vigilance TaskCentre Hospitalier Universitaire de Nīmes
- RECRUITINGPHASE2NCT07096674A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaCentessa Pharmaceuticals (UK) Limited
- RECRUITINGNANCT07006233A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic HypersomniaUniversity of Sydney
- RECRUITINGPHASE2NCT06843590A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaAlkermes, Inc.
- RECRUITINGPHASE2, PHASE3NCT06767683A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaAlkermes, Inc.
- RECRUITINGPHASE2NCT06752668A Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaCentessa Pharmaceuticals (UK) Limited
- RECRUITINGNANCT06457945Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM IntrusionsHospices Civils de Lyon